Adverum Biotechnologies, Inc. Logo

Adverum Biotechnologies, Inc.

A clinical-stage company developing gene therapies for ocular diseases.

ADVM | US

Overview

Corporate Details

ISIN(s):
US00773U2078
LEI:
Country:
United States of America
Address:
100 CARDINAL WAY, 94063 REDWOOD CITY

Description

Adverum Biotechnologies, Inc. is a clinical-stage company developing gene therapies for highly prevalent ocular diseases. The company's primary goal is to establish single-administration intravitreal (IVT) gene therapy as a new standard of care, aspiring to develop functional cures that restore vision and prevent blindness. Its lead product candidate, Ixo-vec (ixoberogene soroparvovec), targets wet age-related macular degeneration (wet AMD). Adverum utilizes a proprietary adeno-associated virus (AAV) vector platform designed to transform retinal cells into biofactories for the long-term production of therapeutic proteins. This approach aims to replace the need for frequent eye injections with a durable, in-office treatment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-19 22:00
15-12G
English DOC 8.0 KB
2025-12-12 06:15 English DOC 5.2 KB
2025-12-12 06:15 English DOC 5.2 KB
2025-12-12 06:15 English DOC 5.2 KB
2025-12-10 19:52 English DOC 10.6 KB
2025-12-10 19:49 English DOC 10.5 KB
2025-12-10 19:46 English DOC 10.2 KB
2025-12-10 19:44 English DOC 10.5 KB
2025-12-10 19:41 English DOC 10.4 KB
2025-12-10 19:38 English DOC 9.3 KB
2025-12-10 19:36 English DOC 9.5 KB
2025-12-10 19:34 English DOC 9.4 KB
2025-12-10 19:31 English DOC 9.7 KB
2025-12-10 19:29 English DOC 9.7 KB
2025-12-10 19:27 English DOC 9.4 KB

Automate Your Workflow. Get a real-time feed of all Adverum Biotechnologies, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adverum Biotechnologies, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Adverum Biotechnologies, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS
Basilea Pharmaceutica AG Logo
Biopharmaceutical firm developing drugs for severe bacterial and fungal infections.
Switzerland
BSLN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.